Hims & Hers Health (NYSE:HIMS) Issues Earnings Results

Hims & Hers Health (NYSE:HIMS) issued its quarterly earnings results on Monday. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26, Briefing.com reports. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the previous year, the company earned ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Stock Up 7.1 %

Hims & Hers Health stock opened at $22.10 on Wednesday. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The company has a 50 day moving average of $18.10 and a 200-day moving average of $18.19. The stock has a market capitalization of $4.75 billion, a PE ratio of 258.03 and a beta of 1.06.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the transaction, the insider now directly owns 176,952 shares of the company’s stock, valued at approximately $2,919,708. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Michael Chi sold 17,304 shares of Hims & Hers Health stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $22.00, for a total value of $380,688.00. Following the sale, the insider now directly owns 193,980 shares in the company, valued at $4,267,560. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the transaction, the insider now owns 176,952 shares of the company’s stock, valued at $2,919,708. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 650,659 shares of company stock worth $11,712,198 over the last ninety days. Company insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HIMS shares. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Bank of America lifted their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Truist Financial upped their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, TD Cowen upped their price target on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.